Henning Gerschewski joined Rentschler Biopharma as vice president, manufacturing science and technology. Gerschewski has more than 15 years of experience in cell culture cultivation, downstream processing, and technology transfer.
“We are happy to welcome Henning Gerschewski back to the Rentschler family,” Ralf Otto, COO, Rentschler, told GEN. “We believe that his exceptional knowledge and track record in process and technology transfer activities will further strengthen our technology leadership position within the CDMO market.”
According to Otto, Gerschewski will focus on translating medical research into novel biopharmaceuticals. “He will lead the translation of our strategy into new technology opportunities and applications, matching our client’s needs with market trends,” added Otto.
“I am very excited to be returning to Rentschler Biopharma,” said Gerschewski. “The biopharmaceutical industry requires first-in-class development and manufacturing processes to enable the production and launch of innovative therapies. This is our contribution to helping patients with serious or rare diseases.”
Prior to joining Rentschler, Gerschewski worked in various roles of increasing responsibility at Boehringer Ingelheim, most recently as director, process transfer and technical operations. Between 2002 and 2006, he was team leader, downstream processing at Rentschler. Gerschewski has a degree in bioprocess engineering from the University of Applied Sciences in Flensburg, Germany.
Separately, Rentschler completed the acquisition of a manufacturing facility from an affiliate of Shire plc. The 93,000-square-foot site is located in Milford, MA. Under the terms of the agreement, Rentschler will continue to manufacture for Shire at the site.
